Targeting chromatin remodeling complex ARID1A or its downstream effector NF-κB can also reshape the immunosuppressive TME by inducing IFN expression and reducing PMN-MDSC recruitment, thereby offering benefits to anti-PD1/CTLA-4 for cancer treatment (38, 43). Here, IFNA1 is linked to cancer.